PharmaCielo (TSE:PCLO)
:PCLO
Want to see TSE:PCLO full AI Analyst Report?
PCLO Stock Chart & Stats
C$0.04
<C$0.01(5.56%)
At close: 4:00 PM EST
C$0.04
<C$0.01(5.56%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume2.00K
Average Volume (3M)0.00
Market Cap
C$13.85M
Enterprise ValueC$32.46M
Total Cash (Recent Filing)C$289.24K
Total Debt (Recent Filing)C$18.65M
Price to Earnings (P/E)5.2
Beta-3.02
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding187,983,690
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Standardized Cannabinoid SupplierA B2B model supplying standardized cannabinoid inputs to medical and wellness manufacturers is a durable structural advantage: it targets institutional buyers seeking consistent raw ingredients, enabling scale in extraction/processing and longer-term contract opportunities that reduce retail channel complexity and margin pressure.
Positive Gross Margin On Product SalesA mid-high single-digit to high gross margin on product sales demonstrates viable unit economics for extraction and formulation. If oversight of SG&A and cost structure continues, these unit margins provide a realistic path to operating leverage as volumes recover, supporting sustainable profitability over time.
Reduced Cash Burn Vs Prior YearsMaterial reduction in operating cash outflows versus earlier years reflects progress in operational discipline and cost control. Sustained improvement in cash generation trajectory lowers near-term refinancing pressure and increases the chance management can reach break-even without persistent dilutive capital raises.
Bears Say
Declining And Volatile RevenueFalling and inconsistent revenue undermines the company's ability to absorb fixed cultivation and processing costs, makes margin improvement fragile, and complicates long-range planning. Persistent top-line weakness extends reliance on external funding and slows progress toward scalable, self-sustaining operations.
Negative Equity & High LeverageNegative equity combined with debt materially exceeding reported assets creates refinancing and solvency risk. This capital structure limits strategic optionality, increases the likelihood of covenant issues or dilutive recapitalizations, and constrains investment in capacity or commercial expansion.
Deep Operating Losses And Negative Cash FlowLarge operating losses and ongoing negative operating and free cash flow mean the business currently destroys value and requires ongoing external capital. Continued losses erode competitor positioning, limit R&D or market development spend, and make long-term recovery dependent on sustained revenue growth or fresh financing.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$13.85M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is Jun 01, 2026 which is in 12 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 187,983,690 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---